Shots:

• The ESC has published new clinical practice guidelines to manage diabetes and CCS- replacing 2013 recommendations for the management of stable coronary artery disease and recommends Bayer’s Xarelto (2.5mg- bid) + Aspirin (qd) to treat patients with chronic coronary syndromes at high risk of further events and low risk of bleeding
• The recommendation is based on P-III COMPASS study assessing Xarelto + Aspirin vs Aspirin as monothx. resulting in a 24% reduction in the risk of stroke- CV deaths and heart attack with 42% relative risk reduction in stroke and 18% reduction in mortality
• Xarelto is a non-vitamin K antagonist oral anticoagulant- approved for eight indications- protecting patients for more venous and arterial thromboembolic (VAT) conditions. The guidelines also include the change in nomenclature from “stable CAD” to ‘’CCS”- reflecting the continued high risk of heart attacks- strokes and death within the patient population

Click here to­ read full press release/ article | Ref: Bayer | Image: Tamav